TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
TACE is widely used in patients with unresectable HCC. However, it is a non-curative
approach; thus ,strategies to further improve the survival of these patients are needed.
Sorafenib is regarded as standard treatment for advanced HCC. It is the first systemic
therapy to demonstrate a significant survival benefit in HCC patients.The hypothesis is that
the combination of TACE with sorafenib could improve the survival of patients with
unresectable HCC.